Bill Anderson, Bayer CEO (Krisztian Bocsi/Bloomberg via Getty Images)
November 8, 2023 06:50 AM ESTUpdated 11:45 AM
R&D
Pharma

Bay­er un­veils big changes to busi­ness and head­count to ad­dress ‘not ac­cept­able’ per­for­mance

Ayisha Sharma

News Reporter

Bay­er is on a mis­sion to over­haul its busi­ness struc­ture and cut down its man­age­ment lay­ers in a bid to ad­dress plum­met­ing fi­nan­cial per­for­mance, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times